Esperion Therapeutics Inc. (NASDAQ:ESPR) shares, rose in value, with the stock price down by -6.39% to the previous day’s close as strong demand from buyers drove the stock to $2.05.
Actively observing the price movement in the last trading, the stock closed the session at $2.19. The value of beta (5-year monthly) was 0.82. Referring to stock’s 52-week performance, its high was $4.37, and the low was $0.70. On the whole, ESPR has fluctuated by -19.29% over the past month.
With the market capitalization of Esperion Therapeutics Inc. currently standing at about $349.36 million, investors are eagerly awaiting this quarter’s results, scheduled for May 07, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.01, which is expected to increase to -$0.15 for fiscal year -$0.44 and then to about $0.2 by fiscal year 2025. Data indicates that the EPS growth is expected to be 78.30% in 2025, while the next year’s EPS growth is forecast to be 145.50%.
Analysts have estimated the company’s revenue for the quarter at $76.86 million, with a low estimate of $28.9 million and a high estimate of $141.69 million. According to the average forecast, sales growth in current quarter could jump up 215.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $257.54 million, representing an increase of 121.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ESPR’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ESPR currently trading nearly -17.64% and -16.51% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.55, while the 7-day volatility ratio is showing 7.14% which for the 30-day chart, stands at 9.18%. Furthermore, Esperion Therapeutics Inc. (ESPR)’s beta value is 0.82, and its average true range (ATR) is 0.22.
A comparison of Esperion Therapeutics Inc. (ESPR) with its peers suggests the former has fared considerably weaker in the market. ESPR showed an intraday change of -6.39% in last session, and over the past year, it shrunk by -49.00%%.
Data on historical trading for Esperion Therapeutics Inc. (NASDAQ:ESPR) indicates that the trading volumes over the past 10 days have averaged 3.18 million and over the past 3 months, they’ve averaged 6.37 million. According to company’s latest data on outstanding shares, there are 170.42 million shares outstanding.
Nearly 0.53% of Esperion Therapeutics Inc.’s shares belong to company insiders and institutional investors own 48.10% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 16.95 million shares as on Feb 29, 2024, resulting in a short ratio of 3.47. According to the data, the short interest in Esperion Therapeutics Inc. (ESPR) stood at 9.16% of shares outstanding as of Feb 29, 2024; the number of short shares registered in Jan 31, 2024 reached 20.07 million. The stock has fallen by -31.44% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ESPR stock heading into the next quarter.
